摘要
目的:分析血清胸苷激酶1(STK1)的检测在非小细胞肺癌诊断及疗效评估中的意义。方法:选择我院及同济医院2014年5月~2015年5月收治的非小细胞肺癌患者60例,设置为a组,另同期选择健康体检者60例,设置为b组,对比两组受检者的血清STK1水平。结果:a组受检者术前的血清STK1水平相比b组明显较高,术后1个月的血清STK1水平明显低于术前,P<0.05;疾病复发9例,未复发39例,复发患者手术治疗后随访12个月的血清STK1水平明显高于未复发的血清STK1水平,P<0.05;鳞癌的血清STK1水平明显高于腺癌,P<0.05。结论:对非小细胞肺癌患者来说,检测血清STK1水平的临床意义重大,有利于疾病的诊断、治疗与预后的评估。
Objective:Objective to analyze the serum of thymidine kinase 1 (STK1) detection in lung cancer diagnosis and curative effect evaluation of significance.Methods:From May 2014 to May 2015 were 60 patients with Fung cancer,set to group a,the other at the same time choose 60 cases of healthy check-up,set to group b,compared two groups of subjects of blood serum STK1 level.Results:Patients in group a preoperative blood serum STK1 level significantly higher than group b,after 1 month of blood serum STK1 level significantly lower than the preoperative.P 〈 0.05;Relapse 9 cases,39 cases of recurrence,patients with recurrence after surgery were followed up for 12 months of blood serum STK1 level obviously higher than that of without recurrence of blood serum STK1 level,P 〈 0.05;Squamous cell carcinomas of the blood serum STK1 level obviously higher than that of adenocarciooma,P 〈 0.05).Conclusion:For patients with lung cancer,clinical detection of blood serum STK1 level is of great significance,is conducive to disease diagnosis,treatment and prognosis assessment.
出处
《中国医药导刊》
2017年第5期435-437,共3页
Chinese Journal of Medicinal Guide
基金
2012年度武汉市卫生局临床医学科研项目(编号:WX12D13)
项目名称:血清胸苷激酶1在肺癌的早期检测及疗效评估的研究
关键词
非小细胞肺癌
诊断
疗效
血清胸苷激酶
Lung cancer
Diagnosis
Curative effect
Serum thymidine kinase